Ionis Pharmaceuticals Financial Statements
Ionis Pharmaceuticals Financial Overview
Ionis Pharmaceuticals's market cap is currently ―. The company's EPS TTM is $-0.213; its P/E ratio is -213.65; Ionis Pharmaceuticals is scheduled to report earnings on August 9, 2022, and the estimated EPS forecast is $-0.61. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 141.92M | $ 440.01M | $ 133.09M | $ 125.75M | $ 111.61M |
| Gross Profit | $ 137.75M | $ 437.78M | $ 130.01M | $ 122.79M | $ 109.03M |
| EBIT | $ -63.27M | $ 222.10M | $ -81.43M | $ -78.19M | $ -88.24M |
| EBITDA | $ -58.38M | $ 227.09M | $ -76.73M | $ -73.18M | $ -83.38M |
| Net Income Common Stockholders | $ -65.17M | $ 224.61M | $ -82.47M | $ -80.88M | $ -89.87M |
| Balance Sheet | |||||
| Cash, Cash Equivalents and Short-Term Investments | $ 1.82B | $ 1.89B | $ 1.99B | $ 2.05B | $ 2.06B |
| Total Assets | $ 2.52B | $ 2.61B | $ 2.41B | $ 2.50B | $ 2.25B |
| Total Debt | $ 627.05M | $ 820.66M | $ 935.96M | $ 1.29B | $ 1.31B |
| Net Debt | $ -1.19B | $ -1.07B | $ -1.05B | $ -760.67M | $ -748.73M |
| Total Liabilities | $ 1.81B | $ 1.84B | $ 1.88B | $ 1.91B | $ 1.57B |
| Stockholders Equity | $ 530.54M | $ 582.67M | $ 680.56M | $ 709.57M | $ 743.28M |
| Cash Flow | |||||
| Free Cash Flow | $ -35.18M | $ 199.70M | $ -60.17M | $ -68.96M | $ -57.66M |
| Operating Cash Flow | $ -31.65M | $ 203.69M | $ -55.57M | $ -62.65M | $ -54.66M |
| Investing Cash Flow | $ -287.55M | $ 95.11M | $ 121.97M | $ -101.03M | $ 78.86M |
| Financing Cash Flow | $ -7.33M | $ -62.49M | $ 1.46M | $ 314.54M | $ -7.58M |